Sarah Sammons/LinkedIn
May 27, 2025, 10:32
Sarah Sammons: Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow MBC
Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on LinkedIn:
“Join me and my esteemed colleagues for a discussion on the emerging biomarkers of HER2 low and ultra-low, a deep dive into Destiny Breast 04 and 06 data, optimal positioning of T-DXd, and most importantly patient selection and toxicity management considerations.”
Sarah Sammons previewed an upcoming expert discussion focused on HER2 low and ultra-low biomarkers, recent Destiny Breast clinical trial data, and strategies for effective use of T-DXd including patient selection and toxicity management.
More posts featuring Sarah Sammons.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 16, 2025, 18:35
Jun 16, 2025, 16:15
Jun 16, 2025, 16:01
Jun 16, 2025, 15:19